Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: A retrospective case series  Nicolas Noel, MD, MSc, Nizar Mahlaoui, MD, MSc, MPH, Stéphane Blanche, MD, PhD, Felipe Suarez, MD, PhD, Hélène Coignard- Biehler, MD, Isabelle Durieu, MD, PhD, Philippe Godeberge, MD, Harry Sokol, MD, PhD, Emilie Catherinot, MD, PhD, Sylvain Poiree, MD, Hugo Chapdelaine, MD, Bertrand Dunogue, MD, MSc, Christine Bodemer, MD, PhD, Marc Lecuit, MD, PhD, Alain Fischer, MD, PhD, Olivier Lortholary, MD, PhD, Olivier Hermine, MD, PhD  Journal of Allergy and Clinical Immunology  Volume 132, Issue 4, Pages 997-1000.e4 (October 2013) DOI: 10.1016/j.jaci.2013.04.059 Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Crohn-like disease in patient 4 at thalidomide's initiation. A, Endoscopic evaluation showing multiple ulcerations and aphthae. B, Colonic mucosa: neutrophilic and macrophagic infiltration (thin arrow) and presence of granulomas (large arrow) in the lamina propria. Journal of Allergy and Clinical Immunology 2013 132, 997-1000.e4DOI: (10.1016/j.jaci.2013.04.059) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E2 Pulmonary involvement of patient 6 (CT scan evaluation). A, Sarcoid-like bilateral consolidations in the central position with traction bronchiectasis at thalidomide's introduction. B, Improvement in the pseudomass near the aortic cross (27 vs 44 mm) after 6 months. C, Dramatic improvement in the left-side consolidations with slight improvement in the right lung after 12 months. Journal of Allergy and Clinical Immunology 2013 132, 997-1000.e4DOI: (10.1016/j.jaci.2013.04.059) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E3 A, Left apical subpleural consolidation in patient 3. B, Improvement after 13 months. Journal of Allergy and Clinical Immunology 2013 132, 997-1000.e4DOI: (10.1016/j.jaci.2013.04.059) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E4 A, Interstitial lung involvement in patient 4 (CT scan) at thalidomide's introduction. B, No evolution after 6 months of thalidomide therapy. C, No evolution after 14 months of thalidomide therapy. Journal of Allergy and Clinical Immunology 2013 132, 997-1000.e4DOI: (10.1016/j.jaci.2013.04.059) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions